pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
COMPANY OVERVIEW
Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.
LOCATION
San Diego, CA, USA
THERAPEUTIC AREAS
Oncology
WEBSITE
https://www.primmunerx.com
CAREER WEBSITE
None
SOCIAL MEDIA
INVESTORS
PRESS RELEASES
Apr 8, 2022
Primmune Therapeutics Presents Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Mar 28, 2022
Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Mar 21, 2022
Primmune Therapeutics Presents Data Evaluating PRTX007 as an Antiviral at the 35th International Conference on Antiviral Research (ICAR)
Mar 10, 2022
Primmune Therapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference
Feb 24, 2022
Primmune Therapeutics to Participate in the 12th Annual Biocom Global Life Science Partnering Conference
For More Press Releases